Stemness-related lncRNAs signature as a biologic prognostic model for head and neck squamous cell carcinoma

被引:0
作者
Zejun Xu
Min Zhang
Zhiqiang Guo
Lin Chen
Xiaolei Yang
Xiaoyu Li
Qian Liang
Yuqing Tang
Jian Liu
机构
[1] Hainan University,School of Life Sciences
[2] Institute of Biological Anthropology of Jinzhou Medical University,Department of Otolaryngology
[3] Xiangya Hospital,Head and Neck Surgery
[4] Central South University,Department of Pathology
[5] QingPu Branch of Zhongshan Hospital Affiliated to Fudan University,School of Biological Sciences
[6] Community Health Service Center of Zhongshan Street,undefined
[7] Fourth People’s Hospital of Jinan,undefined
[8] University of Texas Southwestern Medical Center,undefined
[9] University of Bristol,undefined
来源
Apoptosis | 2023年 / 28卷
关键词
Head and neck squamous cell carcinoma; LncRNAs; Cancer stem cells; Prognostic model; Immune microenvironment;
D O I
暂无
中图分类号
学科分类号
摘要
Cancer stem cells (CSCs) and long non-coding RNAs (lncRNAs) are particularly important for tumor cell growth and migration, and recurrence and drug resistance, including head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to explore stemness-related lncRNAs (SRlncRNAs) that could be used for prognosis of patients with HNSCC. HNSCC RNA sequencing data and matched clinical data were obtained from TCGA database, and stem cell characteristic genes related to HNSCC mRNAsi were obtained from the online database by WGCNA analysis, respectively. Further, SRlncRNAs were obtained. Then, the prognostic model was constructed to forecast patient survival through univariate Cox regression and LASSO-Cox method based on SRlncRNAs. Kaplan–Meier, ROC and AUC were used to evaluate the predictive ability of the model. Moreover, we probed the underlying biological functions, signalling pathways and immune status hidden within differences in prognosis of patients. We explored whether the model could guide personalized treatments included immunotherapy and chemotherapy for HNSCC patients. At last, RT‐qPCR was performed to analyze the expressions levels of SRlncRNAs in HNSCC cell lines. A SRlncRNAs signature was identified based on 5 SRlncRNAs (AC004943.2, AL022328.1, MIR9-3HG, AC015878.1 and FOXD2-AS1) in HNSCC. Also, risk scores were correlated with the abundance of tumor-infiltrating immune cells, whereas HNSCC-nominated chemotherapy drugs were considerably different from one another. The final finding was that these SRlncRNAs were abnormally expressed in HNSCCCS according to the results of RT-qPCR. These 5 SRlncRNAs signature, as a potential prognostic biomarker, can be utilized for personalized medicine in HNSCC patients.
引用
收藏
页码:860 / 880
页数:20
相关论文
共 486 条
  • [1] Siegel RL(2022)Cancer statistics, 2022 CA Cancer J Clin 72 7-33
  • [2] Miller KD(2020)Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology J Natl Compr Cancer Netw 18 873-898
  • [3] Fuchs HE(2018)Epidemiology and demographics of the head and neck cancer population Oral Maxillofac Surg Clin N Am 30 381-395
  • [4] Jemal A(2021)Prognostic and predictive factors in advanced head and neck squamous cell carcinoma Int J Mol Sci 12 e0170645-573
  • [5] Pfister DG(2017)Contribution of FGFR1 variants to craniofacial variations in East Asians PLoS ONE 85 563-1346
  • [6] Spencer S(2005)Linkage disequilibrium analysis identifies an FGFR1 haplotype-tag SNP associated with normal variation in craniofacial shape Genomics 48 1341-466
  • [7] Adelstein D(2021)Comprehensive genomic and transcriptomic analysis of three synchronous primary tumours and a recurrence from a head and neck cancer patient Int J Mol Sci 41 458-914
  • [8] Adkins D(2012)Population-based evidence of increased survival in human papillomavirus-related head and neck cancer Eur J Cancer 11 1280-8090
  • [9] Anzai Y(2020)Cancer stem cells enrichment with surface markers CD271 and CD44 in human head and neck squamous cell carcinomas Carcinogenesis 43 904-603
  • [10] Brizel DM(2020)Cancer stem cells—origins and biomarkers: perspectives for targeted personalized therapies Front Immunol 47 8075-D773